<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03934814</url>
  </required_header>
  <id_info>
    <org_study_id>TJ011133EDI101</org_study_id>
    <secondary_id>KEYNOTE KN-A21</secondary_id>
    <nct_id>NCT03934814</nct_id>
  </id_info>
  <brief_title>Study of TJ011133 Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma</brief_title>
  <official_title>A Phase 1 Study of TJ011133 Administered Alone or in Combination With Pembrolizumab or Rituximab in Subjects With Relapsed/Refractory Advanced Solid Tumors and Lymphoma</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>I-Mab Biopharma Co. Ltd.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>I-Mab Biopharma Co. Ltd.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>Yes</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to assess the safety and tolerability of TJ011133 in
      participants with solid tumors and lymphoma.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is an open-label, multi-center, multiple dose, Phase 1 study to evaluate the safety,
      tolerability, maximum tolerated dose (MTD) or maximum administered dose (MAD),
      pharmacokinetic (PK), pharmacodynamic, and recommended Phase 2 dose (RP2D) of TJ011133, an
      anti-CD47 antibody, in subjects with advanced relapsed or refractory solid tumors and
      lymphoma. The study will be conducted in 2 parts. Part 1 comprises a single agent dose
      escalation (Part 1A) and 2 separate combination therapy dose escalations (Part 1B with
      pembrolizumab and Part 1C with rituximab) and Part 2 includes a dose expansion study.
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">May 8, 2019</start_date>
  <completion_date type="Anticipated">September 23, 2023</completion_date>
  <primary_completion_date type="Anticipated">February 21, 2022</primary_completion_date>
  <phase>Phase 1</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Sequential Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Dose Limiting Toxicities (DLT)</measure>
    <time_frame>21 or 28 days, depending on Study Part</time_frame>
    <description>Part 1A DLT period is 3 weeks, Part 1B DLT period is 3 weeks, Part 1C DLT period is 4 weeks</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Incidence and Severity of Adverse Events</measure>
    <time_frame>up to 100 days post last dose</time_frame>
    <description>The CTCAE criteria will be used to assess adverse events on this trial.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Maximum Tolerated Dose (MTD) for both monotherapy and combination therapy</measure>
    <time_frame>21 or 28 days, depending on Study Part</time_frame>
    <description>Based on DLT Definitions</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters: Tmax</measure>
    <time_frame>up to 100 days post last dose</time_frame>
    <description>Time of peak concentration (Tmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters: Cmax</measure>
    <time_frame>up to 100 days post last dose</time_frame>
    <description>Maximal concentration (Cmax)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters: T1/2</measure>
    <time_frame>up to 100 days post last dose</time_frame>
    <description>Investigational Product (IP) half-life (T1/2)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic Parameters: CL</measure>
    <time_frame>up to 100 days post last dose</time_frame>
    <description>Investigational Product (IP) Clearance (CL)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Pharmacokinetic (PK) Parameters: AUC∞</measure>
    <time_frame>up to 100 days post last dose</time_frame>
    <description>Area under the curve from time zero extrapolated to infinity (AUC∞)</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Anti-drug antibodies (ADA)</measure>
    <time_frame>up to 100 days post last dose</time_frame>
    <description>Incidence and concentration of anti-drug antibodies</description>
  </secondary_outcome>
  <number_of_arms>4</number_of_arms>
  <enrollment type="Anticipated">88</enrollment>
  <condition>Solid Tumor</condition>
  <condition>Lymphoma</condition>
  <arm_group>
    <arm_group_label>Part 1A - TJ011133 Monotherapy</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TJ011133 alone will be administered at up to 6 dose levels (0.3, 1, 3, 10, 20, or 30 mg/kg) once weekly (Q1W) (the 0.3 mg/kg dose level cohort will be enrolled if a DLT in 1 out of 3 subjects is observed following the 1 mg/kg dose level)</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1B - Combination therapy of TJ011133 with pembrolizumab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TJ011133 will be administered Q1W, starting at one dose level below MTD or MAD in monotherapy arm, in combination with pembrolizumab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 1C -Combination therapy of TJ011133 with rituximab</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>TJ011133 will be administered Q1W, starting at one dose level below MTD or MAD in monotherapy arm, in combination with rituximab</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Part 2 - Dose Expansion</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>20 subjects (with DLBCL or indolent lymphoma) in the TJ011133 combination therapy with rituximab expansion and 20 subjects with solid tumors in the TJ011133 combination therapy with pembrolizumab expansion.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>TJ011133</intervention_name>
    <description>TJ011133 will be administered weekly</description>
    <arm_group_label>Part 1A - TJ011133 Monotherapy</arm_group_label>
    <arm_group_label>Part 1B - Combination therapy of TJ011133 with pembrolizumab</arm_group_label>
    <arm_group_label>Part 1C -Combination therapy of TJ011133 with rituximab</arm_group_label>
    <arm_group_label>Part 2 - Dose Expansion</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Pembrolizumab</intervention_name>
    <description>Pembrolizumab will be administered every 3 weeks</description>
    <arm_group_label>Part 1B - Combination therapy of TJ011133 with pembrolizumab</arm_group_label>
    <arm_group_label>Part 2 - Dose Expansion</arm_group_label>
    <other_name>Keytruda</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Rituximab</intervention_name>
    <description>Rituximab will be administered weekly for 5 doses, then followed by monthly doses</description>
    <arm_group_label>Part 1C -Combination therapy of TJ011133 with rituximab</arm_group_label>
    <arm_group_label>Part 2 - Dose Expansion</arm_group_label>
    <other_name>Rituxan, MabThera</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Part 1: Subjects with advanced relapsed/refractory solid tumors and lymphoma

          -  Part 2 with Rituximab: Subjects with DLBCL or Indolent B-cell Lymphoma, with at least
             one measurable lesion by Lugano and available fresh metastatic biopsy sample prior to
             study entry.

          -  Part 2 with Pembrolizumab: Subject with locally advanced non-small-cell lung carcinoma
             (NSCLC) with disease progression, Urothelial (bladder) cancer that is not eligible for
             cisplatin-containing chemotherapy or has progressed following cisplatin-containing
             chemotherapy, or immune-oncology treatment naive Epithelial ovarian cancer, fallopian
             tube, or primary peritoneal cancer, with at least one measurable lesion defined by
             RECIST 1.1, and available fresh metastatic biopsy prior to study entry.

          -  All Parts: Eastern Cooperative Oncology Group (ECOG) Performance Status 0 to 1 and
             adequate bone marrow, renal, and liver functions.

        Exclusion Criteria:

          -  Subjects with known symptomatic central nervous system tumors or known central nervous
             system metastases or leptomeningeal disease requiring steroids. Subjects who document
             stable and central nervous system metastases and are off steroids for more than 4
             weeks may be enrolled in the study

          -  Subjects with Burkitt's lymphoma, lymphoblastic lymphoma, Richter's transformation,
             primary effusion lymphoma or chronic lymphocytic leukemia/small lymphocytic lymphoma

          -  Subjects with mantle cell lymphoma

          -  Impaired cardiac function or clinically significant cardiac diseases

          -  Prior treatment with CD47 or SIRPα inhibitors

          -  Prior autologous stem cell transplant ≤3 months prior to starting study

          -  Prior allogeneic stem cell transplant with either standard or reduced intensity
             conditioning

          -  Prior chimeric antigen receptor or chimeric antigen receptor T-cell therapy

          -  History of autoimmune anemia or autoimmune thrombocytopenia

          -  Positive Direct Antiglobulin Test

          -  Active graft versus host disease (GVHD) or ongoing immunosuppression for GVHD
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Claire Xu, MD, PhD</last_name>
    <role>Study Director</role>
    <affiliation>I-Mab Biopharma</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>US Site Head</last_name>
    <phone>301-294-4408</phone>
    <email>us.info@i-mabbiopharma.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>University of Alabama - Birmingham</name>
      <address>
        <city>Birmingham</city>
        <state>Alabama</state>
        <zip>35233</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Dayle Craig</last_name>
      <email>dc0350@uab.edu</email>
    </contact>
    <investigator>
      <last_name>Lakshminarayanan Nandagopal, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Scottsdale</city>
        <state>Arizona</state>
        <zip>85259</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>CANCERCENTERFEDREGREP@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Mahesh Seetharam, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>City of Hope Comprehensive Cancer Center</name>
      <address>
        <city>Duarte</city>
        <state>California</state>
        <zip>91010</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Yan Xing, MD, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Yale School of Medicine</name>
      <address>
        <city>New Haven</city>
        <state>Connecticut</state>
        <zip>06510</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Iris Isufi, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Jacksonville</city>
        <state>Florida</state>
        <zip>32224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <email>CANCERCENTERFEDREGREP@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Winston W Tan, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Horizon Oncology</name>
      <address>
        <city>Lafayette</city>
        <state>Indiana</state>
        <zip>47905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Elizabeth Morris</last_name>
      <phone>765-446-5111</phone>
      <email>eamorris@horizonbioadvance.com</email>
    </contact>
    <investigator>
      <last_name>Wael A Harb, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>University of Michigan</name>
      <address>
        <city>Ann Arbor</city>
        <state>Michigan</state>
        <zip>48109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cancer Answer Line</last_name>
      <phone>800-855-1125</phone>
      <email>canceranswerline@med.umich.edu</email>
    </contact>
    <investigator>
      <last_name>Paul Swiecicki, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Mayo Clinic</name>
      <address>
        <city>Rochester</city>
        <state>Minnesota</state>
        <zip>55905</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Cancer Related Clinical Trials</last_name>
      <phone>855-776-0015</phone>
      <email>CANCERCENTERFEDREGREP@mayo.edu</email>
    </contact>
    <investigator>
      <last_name>Alex A Adjei, M.D., PhD.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>NYU Langone Health</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <zip>10016</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
    <investigator>
      <last_name>Catherine M Diefenbach, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Vanderbilt-Ingram Cancer Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37203</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Clinical Trials Information Program</last_name>
      <phone>800-811-8480</phone>
    </contact>
    <investigator>
      <last_name>Jordan Berlin, MD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location>
    <facility>
      <name>Seattle Cancer Care Alliance</name>
      <address>
        <city>Seattle</city>
        <state>Washington</state>
        <zip>98109</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <investigator>
      <last_name>Ajay K Gopal, M.D.</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>April 26, 2019</study_first_submitted>
  <study_first_submitted_qc>April 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">May 2, 2019</study_first_posted>
  <last_update_submitted>July 20, 2020</last_update_submitted>
  <last_update_submitted_qc>July 20, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 22, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Lymphoma</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Rituximab</mesh_term>
    <mesh_term>Pembrolizumab</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

